en · de · es · pt
melanotan-2-notes.peptides1004.com › Topic › Peptide Identity And Structural Background — Research Overview

Peptide Identity And Structural Background — Research Overview

By Editorial Desk · published 2025-08-26 · last reviewed 2025-09-22 · Topic

melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-22. Numbers and descriptions here follow the published literature rather than marketing material.

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Melanotan II Background and Mechanism

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Related pages on this site

Notes from published material

Even so, they could play a significant role in the shaping of the political landscape.A 2023 poll by The Wall Street Journal and the National Opinion Research Center (NORC) at the University of Chicago found that about 23% of people adults below the age of 30 thought that having children was important, 9 percentage points below those aged 65 and above.

"DEA Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". Federal Register. 6 October 2014. Archived from the original on 10 August 2016. Retrieved 6 October 2014.

An ion source is a device that creates atomic and molecular ions. Ion sources are used to form ions for mass spectrometers, optical emission spectrometers, particle accelerators, ion implanters and ion engines.

== History == SDMA was first mentioned in the scientific literature by 2013, but was only conceptually described at this time. Subsequently, its synthesis and preclinical pharmacology were described by Nina Kastner and colleagues including Matthias Grill at MiHKAL in 2025. In addition, SDMA was patented by Mydecine as a shorter-acting MDMA alternative in 2023. Prodrugs of SDMA and/or related compounds have also been described. The drug is of interest for potential therapeutic use, for instance treatment of post-traumatic stress disorder (PTSD).

=== Endocrine disruption === LeBlanc's research in the field of toxicology, particularly centered on endocrine disruption, has contributed to the understanding of the impact of environmental contaminants on human and wildlife health. He investigated the impacts of endocrine-disrupting chemicals on mammals, fishes, reptiles, and invertebrates. He identified the suite of nuclear receptors in the crustacean, Daphnia pulex, and functionally characterized several of these receptors. He deciphered the neuro-endocrine signaling pathway responsible for sex determination in some crustaceans, including the discovery of the hormone responsible for sex determination, methyl farnesoate, and its receptor protein. He also demonstrated that some insecticides can mimic the action of methyl farnesoate in daphnids resulting in altered sex ratios of offspring. In 2005, LeBlanc created a mathematical model that integrated concentration addition, response addition, and toxicokinetic interactions to enable the assessment of the toxicity of chemical mixtures. He demonstrated the utility of this model by assessing the joint toxicity of 9 chemicals commonly found in surface waters in the US. This model has been used by regulatory agencies and has been recommended by the National Research Council in the assessment of risks to endangered and threatened species from exposure to pesticide mixtures.

Sources: en.wikipedia.org

Background from the literature

Waffle House has developed into a cultural icon. Part of Waffle House's fame is that they are prominent along Interstate highways in the South. A now defunct GeoCities website, The Waffle House Shrine, hosted employee and customer comments about their experiences with Waffle House. Waffle House has become known as an Internet meme for viral videos of fights on its premises, which have been attributed to the combination of being open 24/7 and its customers often being under the influence of alcohol, though this reputation has been described as a self-fulfilling prophecy with similar violence regularly taking place in other retail outlets.

== Development == Affimer proteins were developed initially at the MRC Cancer Cell Unit in Cambridge then across two laboratories at the University of Leeds. Derived from the cysteine protease inhibitor family of cystatins, which function in nature as cysteine protease inhibitors, these 12–14 kDa proteins share the common tertiary structure of an alpha-helix lying on top of an anti-parallel beta-sheet. Affimer proteins display two peptide loops that can all be randomized to bind to desired target proteins, in a similar manner to monoclonal antibodies. Stabilization of the two peptides by the protein scaffold constrains the possible conformations that the peptides can take. This increases the binding affinity and specificity compared to libraries of free peptides, though can limit the target repertoire of Affimers.

Jennifer Ann Kiggans (née Moore; born June 18, 1971) is an American politician, former United States Navy helicopter pilot, and geriatric nurse practitioner serving as the U.S. representative for Virginia's 2nd congressional district since 2023. A member of the Republican Party, she previously served in the Virginia Senate from 2020 to 2022. Kiggans was first elected to the House in 2022, defeating Democratic incumbent Elaine Luria. She was re-elected in 2024.

== Status at birth == As with many other European monarchs during World War II, King Peter II left his country to establish a government-in-exile. He left Yugoslavia in April 1941 and arrived in London in June 1941. The Royal Yugoslav Armed Forces capitulated in 18 April. After the Tehran Conference, the Allies shifted support from royalist Chetniks to communist-led Partisans. Commenting on the event and what happened to his father, Crown Prince Alexander said, "He [Peter II] was too straight. He could not believe that his allies – the mighty American democracy and his relatives and friends in London – could do him in. But that's precisely what happened". In June 1944, Ivan Šubašić, the Royalist prime minister, and Josip Broz Tito, the Communist Partisan leader, signed an agreement that was an attempt to merge the royal government and communist movement. On 29 November 1943, AVNOJ (formed by the Partisans) declared themselves the sovereign communist government of Yugoslavia and announced that they would take away all legal rights from the Royal government. On 10 August 1945, less than a month after Alexander's birth, AVNOJ named the country Democratic Federal Yugoslavia. On 29 November 1945, the country was declared a communist republic and changed its name to People's Federal Republic of Yugoslavia. In 1947, all members of Alexander's family except for his granduncle Prince George were deprived of their Yugoslav citizenship and their property was confiscated.

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

Network